Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia

•Treatment of relapsed refractory T-PLL with venetoclax monotherapy results in only transient and minor clinical responses.•In vitro analyses pre- and postvenetoclax indicate dual dependence on BCL2 and MCL1; combined BCL2 and MCL1 inhibition are synergistic.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood advances 2020-02, Vol.4 (3), p.525-529
Hauptverfasser:	Smith, Victoria M., Lomas, Oliver, Constantine, Donna, Palmer, Lianne, Schuh, Anna H., Bruce, David, Gonchar, Oksana, Macip, Salvador, Jayne, Sandrine, Dyer, Martin J.S., Eyre, Toby A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Apoptosis Female Humans Leukemia, Prolymphocytic, T-Cell - diagnosis Leukemia, Prolymphocytic, T-Cell - genetics Middle Aged Myeloid Cell Leukemia Sequence 1 Protein - genetics Proto-Oncogene Proteins c-bcl-2 - genetics Stimulus Report
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	•Treatment of relapsed refractory T-PLL with venetoclax monotherapy results in only transient and minor clinical responses.•In vitro analyses pre- and postvenetoclax indicate dual dependence on BCL2 and MCL1; combined BCL2 and MCL1 inhibition are synergistic.
ISSN:	2473-9529 2473-9537
DOI:	10.1182/bloodadvances.2019000917